AstraZeneca's Daxas turned down by NICE for NHS use in adult patients with chronic bronchitis

Amy Schofield 14 February 2017

AstraZeneca's chronic obstructive pulmonary disease (COPD) drug Daxas (roflumilast) has been turned down in draft guidance by the National Institute for Health and Care Excellence (NICE) for NHS use.

AstraZeneca had submitted roflumilast to be considered in adult patients with chronic bronchitis and frequent exacerbations, to be used as an effective oral treatment for adults when combined with current bronchodilator treatment options.

At £18,774, AstraZeneca calculated the drug’s price per quality-adjusted life-year (QALY) far lower than NICE’s calculation, at £71,365.


NICE therefore deemed Daxas as currently too expensive to be viable for widespread use on the NHS. 

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.